[go: up one dir, main page]

WO2003018615A1 - Nouveau cristal de compose lipopeptidique cyclique - Google Patents

Nouveau cristal de compose lipopeptidique cyclique Download PDF

Info

Publication number
WO2003018615A1
WO2003018615A1 PCT/JP2002/008694 JP0208694W WO03018615A1 WO 2003018615 A1 WO2003018615 A1 WO 2003018615A1 JP 0208694 W JP0208694 W JP 0208694W WO 03018615 A1 WO03018615 A1 WO 03018615A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
around
acetone
cyclic lipopeptide
lipopeptide compound
Prior art date
Application number
PCT/JP2002/008694
Other languages
English (en)
Japanese (ja)
Inventor
Kazumi Kawai
Katsuhiko Ito
Tomoji Higaki
Mitsunori Matsuda
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of WO2003018615A1 publication Critical patent/WO2003018615A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This compound has antimicrobial activity (especially antifungal activity) and 8-1,3-glucan synthase inhibitory activity, and is effective in preventing Pneumocystis carinii infections, such as pneumocystis pneumonia. It is useful for prevention and treatment of various infectious diseases including. Background art
  • the B82 type crystal of compound (I) obtained by the above production method is filtered and dried by a conventional method.
  • the B82 type crystal of the compound (I) has extremely excellent advantages, and is very superior to the amorphous compound (I).
  • Test sample 1 Amorphous compound (I) obtained in Example 25 in WO966Z11210
  • FIG. 1 shows a powder X-ray diffraction pattern of the B82 type 2 crystal.
  • FIG. 2 shows an infrared absorption spectrum (KBr method) of the B82 type crystal.
  • Figure 1 shows the powder X-ray diffraction pattern.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des cristaux d'un composé lipopeptidique cyclique (I) représenté par la structure chimique (I). On peut obtenir ces cristaux par dissolution du composé lipopeptidique cyclique (I) dans un alcool hydraté ou une acétone hydratée, puis par ajout d'acétate d'éthyle, de dichlorométhane, d'acétone, d'acétonitrile ou d'un mélange de deux au moins de ces composés dans la solution avec un refroidissement ou un chauffage.
PCT/JP2002/008694 2001-08-31 2002-08-28 Nouveau cristal de compose lipopeptidique cyclique WO2003018615A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-263320 2001-08-31
JP2001263320A JP2005053782A (ja) 2001-08-31 2001-08-31 環状リポペプチド化合物の新規結晶

Publications (1)

Publication Number Publication Date
WO2003018615A1 true WO2003018615A1 (fr) 2003-03-06

Family

ID=19090093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008694 WO2003018615A1 (fr) 2001-08-31 2002-08-28 Nouveau cristal de compose lipopeptidique cyclique

Country Status (3)

Country Link
JP (1) JP2005053782A (fr)
AR (1) AR036317A1 (fr)
WO (1) WO2003018615A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101712B2 (en) 2006-10-16 2012-01-24 TEVA Gyógyszergyár Zártkör{acute over ())}{acute over (})}úen M{acute over ())}{acute over (})}úköd{acute over ())}{acute over (})}ó Részvénytársaság Purification processes for echinocandin-type compounds
WO2013143501A1 (fr) 2012-03-30 2013-10-03 上海天伟生物制药有限公司 Hydrate d'un composé cyclopeptidique, son procédé de préparation et son utilisation
WO2013143497A1 (fr) 2012-03-30 2013-10-03 上海天伟生物制药有限公司 Composé de cyclopeptide de grande pureté et procédé de préparation et utilisation associés
CN104788545A (zh) * 2014-05-29 2015-07-22 上海天伟生物制药有限公司 一种环肽类化合物的结晶粉末及其制备方法和用途
CN104861043A (zh) * 2014-05-29 2015-08-26 上海天伟生物制药有限公司 一种环肽类化合物的组合物及其制备方法和用途
CN104877012A (zh) * 2014-05-29 2015-09-02 上海天伟生物制药有限公司 环肽类化合物的晶体及其制备方法和用途
EP2832743A4 (fr) * 2012-03-30 2015-09-23 Shanghai Techwell Biopharm Co Cristal de cyclopeptide de grande pureté et procédé de préparation et utilisation associés
EP3150623A4 (fr) * 2014-05-29 2017-12-20 Shanghai Techwell Biopharmaceutical Co., Ltd Solvate d'un composé peptidique cyclique, son procédé de préparation et ses utilisations
CN108752430A (zh) * 2018-05-31 2018-11-06 杭州中美华东制药有限公司 米卡芬净钠新晶型及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2583262C2 (ru) * 2011-04-20 2016-05-10 Кселлия Фармасьютикалз Апс Способ очистки микафунгина
KR20250088544A (ko) * 2022-10-20 2025-06-17 추가이 세이야쿠 가부시키가이샤 고리형 펩티드 결정을 제조하는 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0511866A2 (fr) * 1991-05-01 1992-11-04 Merck & Co. Inc. Procédé pour la cristalisation de lipopeptides cicliques
WO1996011210A1 (fr) * 1994-10-07 1996-04-18 Fujisawa Pharmaceutical Co., Ltd. Hexapeptides cycliques a activite antibiotique
WO2000052037A1 (fr) * 1999-03-03 2000-09-08 Eli Lilly And Company Complexes d'echinocandine/glucide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0511866A2 (fr) * 1991-05-01 1992-11-04 Merck & Co. Inc. Procédé pour la cristalisation de lipopeptides cicliques
WO1996011210A1 (fr) * 1994-10-07 1996-04-18 Fujisawa Pharmaceutical Co., Ltd. Hexapeptides cycliques a activite antibiotique
WO2000052037A1 (fr) * 1999-03-03 2000-09-08 Eli Lilly And Company Complexes d'echinocandine/glucide

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101712B2 (en) 2006-10-16 2012-01-24 TEVA Gyógyszergyár Zártkör{acute over ())}{acute over (})}úen M{acute over ())}{acute over (})}úköd{acute over ())}{acute over (})}ó Részvénytársaság Purification processes for echinocandin-type compounds
EP2832743A4 (fr) * 2012-03-30 2015-09-23 Shanghai Techwell Biopharm Co Cristal de cyclopeptide de grande pureté et procédé de préparation et utilisation associés
WO2013143501A1 (fr) 2012-03-30 2013-10-03 上海天伟生物制药有限公司 Hydrate d'un composé cyclopeptidique, son procédé de préparation et son utilisation
WO2013143497A1 (fr) 2012-03-30 2013-10-03 上海天伟生物制药有限公司 Composé de cyclopeptide de grande pureté et procédé de préparation et utilisation associés
RU2607083C2 (ru) * 2012-03-30 2017-01-10 Шанхай Техвелл Биофармасьютикал Ко., Лтд Кристалл циклопептида высокой чистоты, а также способ его получения и его применение
JP2017519042A (ja) * 2014-05-29 2017-07-13 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｔｅｃｈｗｅｌｌ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ シクロペプチド系化合物の組成物およびその製造方法と使用
EP3150621A4 (fr) * 2014-05-29 2017-12-27 Shanghai Techwell Biopharmaceutical Co., Ltd Composition de composé peptidique cyclique, son procédé de préparation et ses utilisations
WO2015180680A1 (fr) * 2014-05-29 2015-12-03 上海天伟生物制药有限公司 Poudre cristalline de composé peptidique cyclique, son procédé de préparation et ses utilisations
WO2015180678A1 (fr) * 2014-05-29 2015-12-03 上海天伟生物制药有限公司 Cristal de composé peptidique cyclique, son procédé de préparation et ses utilisations
JP2016538329A (ja) * 2014-05-29 2016-12-08 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｔｅｃｈｗｅｌｌ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ シクロペプチド系化合物の結晶およびその製造方法と使用
JP2016538330A (ja) * 2014-05-29 2016-12-08 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｔｅｃｈｗｅｌｌ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ シクロペプチド系化合物の結晶粉末およびその製造方法と使用
CN104861043A (zh) * 2014-05-29 2015-08-26 上海天伟生物制药有限公司 一种环肽类化合物的组合物及其制备方法和用途
CN104788545A (zh) * 2014-05-29 2015-07-22 上海天伟生物制药有限公司 一种环肽类化合物的结晶粉末及其制备方法和用途
EP3150623A4 (fr) * 2014-05-29 2017-12-20 Shanghai Techwell Biopharmaceutical Co., Ltd Solvate d'un composé peptidique cyclique, son procédé de préparation et ses utilisations
CN104877012A (zh) * 2014-05-29 2015-09-02 上海天伟生物制药有限公司 环肽类化合物的晶体及其制备方法和用途
CN108276478A (zh) * 2014-05-29 2018-07-13 上海天伟生物制药有限公司 环肽类化合物的晶体及其制备方法和用途
JP7109189B2 (ja) 2014-05-29 2022-07-29 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッド シクロペプチド系化合物の組成物およびその製造方法と使用
US10138274B2 (en) 2014-05-29 2018-11-27 Shanghai Techwell Biopharmaceutical Co., Ltd Crystal of cyclic peptide compound, preparation method for same and uses thereof
US10138275B2 (en) 2014-05-29 2018-11-27 Shanghai Techwell Biopharmaceutical Co., Ltd. Crystalline powder of cyclic peptide compound, preparation method for same, and uses thereof
CN104861043B (zh) * 2014-05-29 2019-03-01 上海天伟生物制药有限公司 一种环肽类化合物的组合物及其制备方法和用途
CN104877012B (zh) * 2014-05-29 2019-03-01 上海天伟生物制药有限公司 环肽类化合物的晶体及其制备方法和用途
CN108276478B (zh) * 2014-05-29 2021-09-28 上海天伟生物制药有限公司 环肽类化合物的晶体及其制备方法和用途
CN113087775A (zh) * 2018-05-31 2021-07-09 杭州中美华东制药有限公司 米卡芬净钠新晶型ii及其制备方法
CN113087775B (zh) * 2018-05-31 2022-07-08 杭州中美华东制药有限公司 米卡芬净钠新晶型ii及其制备方法
CN108752430A (zh) * 2018-05-31 2018-11-06 杭州中美华东制药有限公司 米卡芬净钠新晶型及其制备方法

Also Published As

Publication number Publication date
AR036317A1 (es) 2004-08-25
JP2005053782A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
JP5149810B2 (ja) 無定形、無水結晶形または水和結晶形ドセタキセルの製造方法
WO2003018615A1 (fr) Nouveau cristal de compose lipopeptidique cyclique
WO2014015760A1 (fr) Forme cristallisée de cabazitaxel et son procédé de fabrication
NO339927B1 (no) Krystaller av morfinanderivat og fremgangsmåte for fremstilling derav
JP6491325B2 (ja) シクロペプチド系化合物の溶媒和物およびその製造方法と使用
CN111689905A (zh) 一种奥拉帕尼与马来酸的共晶及其制备方法
KR20140139123A (ko) 고순도 고리형 펩티드계 물질의 결정체 및 그 제조방법과 용도
CN106892900A (zh) 一种富马酸沃诺拉赞及其制备方法
CN114008023B (zh) 索吡溴铵的晶型及其制备方法
EP0629621B1 (fr) Cristal d'hydrate de derive d'acide quinolonecarboxylique
JP2023539298A (ja) カリプラジン医薬組成物、製造方法及び応用
CN107540589B (zh) 一种艾尔骨化醇晶型、药物组合物及制备方法和应用
CN115501186B (zh) 一种黄酮醇糖苷-柠檬酸固体分散体及其制备方法
WO2012010092A1 (fr) Méthode de synthèse et applications d'un cristal de substance peptidique
TW200940485A (en) Preparing method of tamibarotene crystal form II
CN113197865B (zh) 醋酸阿比特龙与反式乌头酸的共晶、其制备方法、药物组合物及其应用
CN107602571A (zh) 枸橼酸艾地那非晶体及其制备方法和药物组合物
CN107163025A (zh) 一种治疗消化系统疾病的药物化合物及其制备方法
EP2726106B1 (fr) Complexe de tomoxiprole amorphe et de cyclodextrine présentant une vitesse de dissolution élevée et son procédé de préparation
CN109153676B (zh) Nbi-98854的晶型及其制备方法和用途
CN114634474B (zh) 双氢杨梅素的共晶化合物及其制备方法
CN105859748B (zh) 多环化合物钠盐及其多晶型、制备方法及应用
JP7201263B2 (ja) Ｃｙｃｌｉｃ－ｄｉ－ＡＭＰナトリウム塩結晶
CN109705076A (zh) 一种达格列净晶型、制备方法及其用途
JPWO2012002189A1 (ja) バルサルタンの製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP